Wang et al. reported that, among 225 pediatric patients treated with CD19/CD22 CAR T cells, 88% developed CRS, with 20.9% experiencing neurotoxicity and three fatal cases of severe CRS, highlighting its lethal risks. The gene discussed is CD22; the disease is congenital rubella syndrome.